#### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

#### Multiple Technology Appraisal (MTA)

# Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85)

#### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors         Accord Healthcare (mycophenolate mofetil, immediate-release tacrolimus)         Actavis (mycophenolate mofetil)         Arrow Pharmaceuticals (mycophenolate mofetil)         Astellas Pharma (immediate-release tacrolimus, prolonged-release tacrolimus)         Bristol-Myers Squibb (belatacept)         Dexcel Pharma (immediate-release tacrolimus)         Dr Reddy's Laboratories (mycophenolate mofetil)         Mylan (mycophenolate mofetil, immediate-release tacrolimus)         Novartis Pharmaceuticals (basiliximab, everolimus, and mycophenolate sodium)         Pfizer (sirolimus)         Roche Products (mycophenolate mofetil, immediate-release tacrolimus)         Sandoz (mycophenolate mofetil, immediate-release tacrolimus)         Sanofi (rabbit anti-human thymocyte immunoglobulin)         Teva (mycophenolate mofetil, immediate-release tacrolimus)         Sanofi (rabbit anti-human thymocyte immunoglobulin)         Teva (mycophenolate mofetil, immediate-release tacrolimus)         Sanofi (rabbit anti-human thymocyte immunoglobulin)         Teva (mycophenolate mofetil, immediate-release tacrolimus)         Sanofi (rabbit anti-human thymocyte immunoglobulin)         Teva (mycophenolate mofetil, immediate-release tacrolimus)         Sanofi (rabbit anti-human thymocyte immunoglobulin)         Teva (mycophenolate mofetil, immediate-release tacrolimus)         Back Health Age	General         • Allied Health Professionals Federation         • Association of Renal Industries         • Board of Community Health Councils in Wales         • British National Formulary         • Care Quality Commission         • Commissioning Support Appraisals Service         • Department of Health, Social Services and Public Safety for Northern Ireland         • Healthcare Improvement Scotland         • Kidney Wales Foundation         • Medicines and Healthcare products Regulatory Agency         • National Association of Primary Care         • NHS Alliance         • NHS Confederation         • Scottish Medicines Consortium         • Welsh Kidney Patients Association         Comparator manufacturers         • Actavis (azathioprine, prednisolone)         • Arrow Generics (azathioprine)         • Aspen Europe (azathioprine)         • Beacon Pharmaceuticals (methylprednisolone)         • Dexcel Pharma (ciclosporin)         • Intrapharm Laboratories (prednisolone)         • Dexcel Pharmaceuticals (prednisolone)         • Metwest Pharmaceuticals (prednisolone)         • Mylan (azathioprine, ciclosporin)         • NHS Robiolone)         • Dexcel Pharmaceuticals (prednisolone)         • Dexcel Pharmaceuticals (prednisolone)         • Dexcel P

National Institute for Health and Care Excellence

Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85)

<ul> <li>Transplant Support Network</li> <li>Professional groups         <ul> <li>Association of Surgeons of Great Britain and Ireland</li> <li>British Association of Urological Nurses</li> <li>British Association of Urological Surgeons</li> <li>British Geriatrics Society</li> <li>British Renal Society</li> <li>British Transplantation Society</li> <li>National Pharmacy Association</li> <li>Renal Association</li> <li>Royal College of Anaesthetists</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Physicians</li> <li>Royal College of Surgeons</li> <li>Royal College of Surgeons</li> <li>Royal College of Mursing</li> <li>Royal College of Surgeons</li> <li>Royal Society of Medicine</li> <li>Society for DGH Nephrologists</li> <li>UK Renal Pharmacy Group</li> <li>United Kingdom Clinical Pharmacy Association</li> <li>Urology Foundation</li> </ul> </li> <li>Others         <ul> <li>Department of Health</li> <li>NHS England</li> <li>NHS Southport and Formby CCG</li> <li>NHS Durham Dales, Easington and Sedgefield CCG</li> <li>Welsh Government</li> </ul> </li> </ul>	<ul> <li>Zentiva (prednisolone)</li> <li><u>Relevant research groups</u></li> <li>Cochrane Renal Group</li> <li>Health Research Authority</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>Research Institute for the Care of Older People</li> <li><u>Assessment Group</u></li> <li>National Institute for Health Research Health Technology Assessment Programme</li> <li>Peninsula Technology Assessment Group (PenTAG)</li> <li><u>Associated Guideline Groups</u></li> <li>National Clinical Guideline Centre for Acute and Chronic Conditions</li> <li><u>Public Health Groups</u></li> <li>Public Health Wales NHS Trust</li> <li>Public Health England</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

## **Definitions:**

National Institute for Health and Care Excellence Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85) Issue date: March 2014 Page 2 of 3

## **Consultees**

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government; relevant NHS organisations in England and local health boards in Wales.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and consultee organisations representing patient/carers and professionals can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

## **Commentators**

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, the *British National Formulary*, and the British Medical Association.

### Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).